Evaluation of GLUT1, IGF-2, VEGF, FGF 1, and angiopoietin 2 in infantile hemangioma
Infantile hemangioma (IH) is a common vascular tumor in children. It is reported that IHs are associated with immunochemical markers such as vascular endothelial growth factor (VEGF)-A, glucose transporter isoform 1 (GLUT1), and insulin-like growth factor-2 (IGF-2). This cross-sectional study focuse...
Gespeichert in:
Veröffentlicht in: | Archives de pédiatrie : organe officiel de la Société française de pédiatrie 2021-05, Vol.28 (4), p.296-300 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 300 |
---|---|
container_issue | 4 |
container_start_page | 296 |
container_title | Archives de pédiatrie : organe officiel de la Société française de pédiatrie |
container_volume | 28 |
creator | Aydin Köker, Sultan Kömüroğlu, Ahmet Ufuk Köksoy, Adem Yasin Şiraz, Ülkü Gül Tekin, Emine Köker, Alper |
description | Infantile hemangioma (IH) is a common vascular tumor in children. It is reported that IHs are associated with immunochemical markers such as vascular endothelial growth factor (VEGF)-A, glucose transporter isoform 1 (GLUT1), and insulin-like growth factor-2 (IGF-2).
This cross-sectional study focused on pediatric patients with IH. A total of 46 patients (mean age 14.2±21.9 months) with IH and 45 healthy controls (mean age 21.8±15.08 months) were enrolled. Demographic data, clinical findings, and laboratory parameters were recorded. Blood samples were collected. Serum GLUT1, IGF-2, VEGF-A, fibroblast growth factor 1 (FGF1), and angiopoietin 2 levels were assessed by enzyme-linked immunosorbent assay.
Serum GLUT1, IGF-2, and VEGF-A levels were significantly higher in patients with IH than in healthy controls (8.80±4.07pg/mL vs. 5.66±4.34pg/mL, 281.10±84.12pg/mL vs. 234.19±75.38pg/mL, 1196.99±389.34pg/mL vs. 996.99±349.16pg/mL, respectively, p=0.026, p=0.030, and p=0.036). Serum GLUT1, IGF-2, and VEGF-A levels in patients with complicated hemangioma were significantly higher than in healthy controls (9.69±3.94pg/mL vs. 5.66±4.34pg/mL, 289.94±83.18pg/mL vs. 234.19±75.38pg/mL, 1276.22±388.24pg/mL vs. 996.99±349.16pg/mL, respectively, p=0.017, p=0.022, and p=0.011). Serum GLUT1, IGF-2, and VEGF-A levels in patients with hemangioma receiving propranolol treatment were significantly higher than in healthy controls. Serum FGF1 levels were higher in patients with IH, complicated hemangioma, and hemangioma receiving propranolol treatment than in healthy controls but the difference was not statistically significantly.
Serum GLUT1, IGF-2, and VEGF-A levels were positively correlated with disease severity in patients with hemangioma, for example, in complicated hemangioma and hemangioma requiring propranolol treatment. However, further research on larger and different age subgroups is warranted to assess these markers. |
doi_str_mv | 10.1016/j.arcped.2021.02.009 |
format | Article |
fullrecord | <record><control><sourceid>proquest_webof</sourceid><recordid>TN_cdi_webofscience_primary_000647651500007CitationCount</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0929693X21000257</els_id><sourcerecordid>2501483579</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-7f486277c656439465c1bc47c64808f6ea3bad5fd079f90db46d67576060842f3</originalsourceid><addsrcrecordid>eNqNkctu1DAYRi0EokPhDRDKEolJ-H2JHW-QqtEkVBqJBS3qznIcGzxK4iFOinh73GbKErHw_Xy-HCP0FkOBAfOPx0JP5mS7ggDBBZACQD5DGyy4zDlnd8_RBiRJfUnvLtCrGI8AUEFFX6ILSgUuJWUb9HV_r_tFzz6MWXBZc7i9wdvsuqlzss2-7Zt6m9VNnaU5PXapfPfhFLyd_ZiRLFV-dHqcfW-zH3Z4XB70a_TC6T7aN-f2Et3W-5vd5_zwpbneXR1yQzmZc-FYxYkQhpecUcl4aXBrWBqzdE3Hraat7krXgZBOQtcy3nFRCg4cKkYcvUTv131PU_i52DirwUdj-16PNixRkRIwq2gpZELZipopxDhZp06TH_T0W2FQDzrVUa061YNOBUQlnSn27nzC0g5p7Sn05C8BH1bgl22Di8bb0di_WBLOmeAlLlMPRKKr_6d3fn78ll1YxjlFP61Rm4Teezupc7zzkzWz6oL_91P-AFaJpDU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2501483579</pqid></control><display><type>article</type><title>Evaluation of GLUT1, IGF-2, VEGF, FGF 1, and angiopoietin 2 in infantile hemangioma</title><source>ScienceDirect</source><source>Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><creator>Aydin Köker, Sultan ; Kömüroğlu, Ahmet Ufuk ; Köksoy, Adem Yasin ; Şiraz, Ülkü Gül ; Tekin, Emine ; Köker, Alper</creator><creatorcontrib>Aydin Köker, Sultan ; Kömüroğlu, Ahmet Ufuk ; Köksoy, Adem Yasin ; Şiraz, Ülkü Gül ; Tekin, Emine ; Köker, Alper</creatorcontrib><description>Infantile hemangioma (IH) is a common vascular tumor in children. It is reported that IHs are associated with immunochemical markers such as vascular endothelial growth factor (VEGF)-A, glucose transporter isoform 1 (GLUT1), and insulin-like growth factor-2 (IGF-2).
This cross-sectional study focused on pediatric patients with IH. A total of 46 patients (mean age 14.2±21.9 months) with IH and 45 healthy controls (mean age 21.8±15.08 months) were enrolled. Demographic data, clinical findings, and laboratory parameters were recorded. Blood samples were collected. Serum GLUT1, IGF-2, VEGF-A, fibroblast growth factor 1 (FGF1), and angiopoietin 2 levels were assessed by enzyme-linked immunosorbent assay.
Serum GLUT1, IGF-2, and VEGF-A levels were significantly higher in patients with IH than in healthy controls (8.80±4.07pg/mL vs. 5.66±4.34pg/mL, 281.10±84.12pg/mL vs. 234.19±75.38pg/mL, 1196.99±389.34pg/mL vs. 996.99±349.16pg/mL, respectively, p=0.026, p=0.030, and p=0.036). Serum GLUT1, IGF-2, and VEGF-A levels in patients with complicated hemangioma were significantly higher than in healthy controls (9.69±3.94pg/mL vs. 5.66±4.34pg/mL, 289.94±83.18pg/mL vs. 234.19±75.38pg/mL, 1276.22±388.24pg/mL vs. 996.99±349.16pg/mL, respectively, p=0.017, p=0.022, and p=0.011). Serum GLUT1, IGF-2, and VEGF-A levels in patients with hemangioma receiving propranolol treatment were significantly higher than in healthy controls. Serum FGF1 levels were higher in patients with IH, complicated hemangioma, and hemangioma receiving propranolol treatment than in healthy controls but the difference was not statistically significantly.
Serum GLUT1, IGF-2, and VEGF-A levels were positively correlated with disease severity in patients with hemangioma, for example, in complicated hemangioma and hemangioma requiring propranolol treatment. However, further research on larger and different age subgroups is warranted to assess these markers.</description><identifier>ISSN: 0929-693X</identifier><identifier>EISSN: 1769-664X</identifier><identifier>DOI: 10.1016/j.arcped.2021.02.009</identifier><identifier>PMID: 33715934</identifier><language>eng</language><publisher>ISSY-LES-MOULINEAUX: Elsevier Masson SAS</publisher><subject>FGF 1 ; GLUT1 ; IGF-2 ; Infantile hemangioma ; Life Sciences & Biomedicine ; Pediatrics ; Science & Technology ; VEGF-A</subject><ispartof>Archives de pédiatrie : organe officiel de la Société française de pédiatrie, 2021-05, Vol.28 (4), p.296-300</ispartof><rights>2021 French Society of Pediatrics</rights><rights>Copyright © 2021 French Society of Pediatrics. Published by Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>5</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000647651500007</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c362t-7f486277c656439465c1bc47c64808f6ea3bad5fd079f90db46d67576060842f3</citedby><cites>FETCH-LOGICAL-c362t-7f486277c656439465c1bc47c64808f6ea3bad5fd079f90db46d67576060842f3</cites><orcidid>0000-0003-1231-3023</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.arcped.2021.02.009$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27929,27930,39263,46000</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33715934$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aydin Köker, Sultan</creatorcontrib><creatorcontrib>Kömüroğlu, Ahmet Ufuk</creatorcontrib><creatorcontrib>Köksoy, Adem Yasin</creatorcontrib><creatorcontrib>Şiraz, Ülkü Gül</creatorcontrib><creatorcontrib>Tekin, Emine</creatorcontrib><creatorcontrib>Köker, Alper</creatorcontrib><title>Evaluation of GLUT1, IGF-2, VEGF, FGF 1, and angiopoietin 2 in infantile hemangioma</title><title>Archives de pédiatrie : organe officiel de la Société française de pédiatrie</title><addtitle>ARCH PEDIATRIE</addtitle><addtitle>Arch Pediatr</addtitle><description>Infantile hemangioma (IH) is a common vascular tumor in children. It is reported that IHs are associated with immunochemical markers such as vascular endothelial growth factor (VEGF)-A, glucose transporter isoform 1 (GLUT1), and insulin-like growth factor-2 (IGF-2).
This cross-sectional study focused on pediatric patients with IH. A total of 46 patients (mean age 14.2±21.9 months) with IH and 45 healthy controls (mean age 21.8±15.08 months) were enrolled. Demographic data, clinical findings, and laboratory parameters were recorded. Blood samples were collected. Serum GLUT1, IGF-2, VEGF-A, fibroblast growth factor 1 (FGF1), and angiopoietin 2 levels were assessed by enzyme-linked immunosorbent assay.
Serum GLUT1, IGF-2, and VEGF-A levels were significantly higher in patients with IH than in healthy controls (8.80±4.07pg/mL vs. 5.66±4.34pg/mL, 281.10±84.12pg/mL vs. 234.19±75.38pg/mL, 1196.99±389.34pg/mL vs. 996.99±349.16pg/mL, respectively, p=0.026, p=0.030, and p=0.036). Serum GLUT1, IGF-2, and VEGF-A levels in patients with complicated hemangioma were significantly higher than in healthy controls (9.69±3.94pg/mL vs. 5.66±4.34pg/mL, 289.94±83.18pg/mL vs. 234.19±75.38pg/mL, 1276.22±388.24pg/mL vs. 996.99±349.16pg/mL, respectively, p=0.017, p=0.022, and p=0.011). Serum GLUT1, IGF-2, and VEGF-A levels in patients with hemangioma receiving propranolol treatment were significantly higher than in healthy controls. Serum FGF1 levels were higher in patients with IH, complicated hemangioma, and hemangioma receiving propranolol treatment than in healthy controls but the difference was not statistically significantly.
Serum GLUT1, IGF-2, and VEGF-A levels were positively correlated with disease severity in patients with hemangioma, for example, in complicated hemangioma and hemangioma requiring propranolol treatment. However, further research on larger and different age subgroups is warranted to assess these markers.</description><subject>FGF 1</subject><subject>GLUT1</subject><subject>IGF-2</subject><subject>Infantile hemangioma</subject><subject>Life Sciences & Biomedicine</subject><subject>Pediatrics</subject><subject>Science & Technology</subject><subject>VEGF-A</subject><issn>0929-693X</issn><issn>1769-664X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>HGBXW</sourceid><recordid>eNqNkctu1DAYRi0EokPhDRDKEolJ-H2JHW-QqtEkVBqJBS3qznIcGzxK4iFOinh73GbKErHw_Xy-HCP0FkOBAfOPx0JP5mS7ggDBBZACQD5DGyy4zDlnd8_RBiRJfUnvLtCrGI8AUEFFX6ILSgUuJWUb9HV_r_tFzz6MWXBZc7i9wdvsuqlzss2-7Zt6m9VNnaU5PXapfPfhFLyd_ZiRLFV-dHqcfW-zH3Z4XB70a_TC6T7aN-f2Et3W-5vd5_zwpbneXR1yQzmZc-FYxYkQhpecUcl4aXBrWBqzdE3Hraat7krXgZBOQtcy3nFRCg4cKkYcvUTv131PU_i52DirwUdj-16PNixRkRIwq2gpZELZipopxDhZp06TH_T0W2FQDzrVUa061YNOBUQlnSn27nzC0g5p7Sn05C8BH1bgl22Di8bb0di_WBLOmeAlLlMPRKKr_6d3fn78ll1YxjlFP61Rm4Teezupc7zzkzWz6oL_91P-AFaJpDU</recordid><startdate>202105</startdate><enddate>202105</enddate><creator>Aydin Köker, Sultan</creator><creator>Kömüroğlu, Ahmet Ufuk</creator><creator>Köksoy, Adem Yasin</creator><creator>Şiraz, Ülkü Gül</creator><creator>Tekin, Emine</creator><creator>Köker, Alper</creator><general>Elsevier Masson SAS</general><general>Elsevier</general><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1231-3023</orcidid></search><sort><creationdate>202105</creationdate><title>Evaluation of GLUT1, IGF-2, VEGF, FGF 1, and angiopoietin 2 in infantile hemangioma</title><author>Aydin Köker, Sultan ; Kömüroğlu, Ahmet Ufuk ; Köksoy, Adem Yasin ; Şiraz, Ülkü Gül ; Tekin, Emine ; Köker, Alper</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-7f486277c656439465c1bc47c64808f6ea3bad5fd079f90db46d67576060842f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>FGF 1</topic><topic>GLUT1</topic><topic>IGF-2</topic><topic>Infantile hemangioma</topic><topic>Life Sciences & Biomedicine</topic><topic>Pediatrics</topic><topic>Science & Technology</topic><topic>VEGF-A</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aydin Köker, Sultan</creatorcontrib><creatorcontrib>Kömüroğlu, Ahmet Ufuk</creatorcontrib><creatorcontrib>Köksoy, Adem Yasin</creatorcontrib><creatorcontrib>Şiraz, Ülkü Gül</creatorcontrib><creatorcontrib>Tekin, Emine</creatorcontrib><creatorcontrib>Köker, Alper</creatorcontrib><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Archives de pédiatrie : organe officiel de la Société française de pédiatrie</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aydin Köker, Sultan</au><au>Kömüroğlu, Ahmet Ufuk</au><au>Köksoy, Adem Yasin</au><au>Şiraz, Ülkü Gül</au><au>Tekin, Emine</au><au>Köker, Alper</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of GLUT1, IGF-2, VEGF, FGF 1, and angiopoietin 2 in infantile hemangioma</atitle><jtitle>Archives de pédiatrie : organe officiel de la Société française de pédiatrie</jtitle><stitle>ARCH PEDIATRIE</stitle><addtitle>Arch Pediatr</addtitle><date>2021-05</date><risdate>2021</risdate><volume>28</volume><issue>4</issue><spage>296</spage><epage>300</epage><pages>296-300</pages><issn>0929-693X</issn><eissn>1769-664X</eissn><abstract>Infantile hemangioma (IH) is a common vascular tumor in children. It is reported that IHs are associated with immunochemical markers such as vascular endothelial growth factor (VEGF)-A, glucose transporter isoform 1 (GLUT1), and insulin-like growth factor-2 (IGF-2).
This cross-sectional study focused on pediatric patients with IH. A total of 46 patients (mean age 14.2±21.9 months) with IH and 45 healthy controls (mean age 21.8±15.08 months) were enrolled. Demographic data, clinical findings, and laboratory parameters were recorded. Blood samples were collected. Serum GLUT1, IGF-2, VEGF-A, fibroblast growth factor 1 (FGF1), and angiopoietin 2 levels were assessed by enzyme-linked immunosorbent assay.
Serum GLUT1, IGF-2, and VEGF-A levels were significantly higher in patients with IH than in healthy controls (8.80±4.07pg/mL vs. 5.66±4.34pg/mL, 281.10±84.12pg/mL vs. 234.19±75.38pg/mL, 1196.99±389.34pg/mL vs. 996.99±349.16pg/mL, respectively, p=0.026, p=0.030, and p=0.036). Serum GLUT1, IGF-2, and VEGF-A levels in patients with complicated hemangioma were significantly higher than in healthy controls (9.69±3.94pg/mL vs. 5.66±4.34pg/mL, 289.94±83.18pg/mL vs. 234.19±75.38pg/mL, 1276.22±388.24pg/mL vs. 996.99±349.16pg/mL, respectively, p=0.017, p=0.022, and p=0.011). Serum GLUT1, IGF-2, and VEGF-A levels in patients with hemangioma receiving propranolol treatment were significantly higher than in healthy controls. Serum FGF1 levels were higher in patients with IH, complicated hemangioma, and hemangioma receiving propranolol treatment than in healthy controls but the difference was not statistically significantly.
Serum GLUT1, IGF-2, and VEGF-A levels were positively correlated with disease severity in patients with hemangioma, for example, in complicated hemangioma and hemangioma requiring propranolol treatment. However, further research on larger and different age subgroups is warranted to assess these markers.</abstract><cop>ISSY-LES-MOULINEAUX</cop><pub>Elsevier Masson SAS</pub><pmid>33715934</pmid><doi>10.1016/j.arcped.2021.02.009</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0003-1231-3023</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0929-693X |
ispartof | Archives de pédiatrie : organe officiel de la Société française de pédiatrie, 2021-05, Vol.28 (4), p.296-300 |
issn | 0929-693X 1769-664X |
language | eng |
recordid | cdi_webofscience_primary_000647651500007CitationCount |
source | ScienceDirect; Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /> |
subjects | FGF 1 GLUT1 IGF-2 Infantile hemangioma Life Sciences & Biomedicine Pediatrics Science & Technology VEGF-A |
title | Evaluation of GLUT1, IGF-2, VEGF, FGF 1, and angiopoietin 2 in infantile hemangioma |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T18%3A12%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20GLUT1,%20IGF-2,%20VEGF,%20FGF%201,%20and%20angiopoietin%202%20in%20infantile%20hemangioma&rft.jtitle=Archives%20de%20p%C3%A9diatrie%20:%20organe%20officiel%20de%20la%20Soci%C3%A9t%C3%A9%20fran%C3%A7aise%20de%20p%C3%A9diatrie&rft.au=Aydin%20K%C3%B6ker,%20Sultan&rft.date=2021-05&rft.volume=28&rft.issue=4&rft.spage=296&rft.epage=300&rft.pages=296-300&rft.issn=0929-693X&rft.eissn=1769-664X&rft_id=info:doi/10.1016/j.arcped.2021.02.009&rft_dat=%3Cproquest_webof%3E2501483579%3C/proquest_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2501483579&rft_id=info:pmid/33715934&rft_els_id=S0929693X21000257&rfr_iscdi=true |